60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, regulatory-filing
TL;DR
60 Degrees Pharma filed an 8-K on Aug 26th covering other events and financials.
AI Summary
On August 26, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware with its principal executive office in Washington, D.C., is involved in the pharmaceutical preparations industry.
Why It Matters
This 8-K filing provides an update on the company's activities and financial status, which is crucial for investors to assess its current standing and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for other events and financial statements, not indicating any immediate or significant risks.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- August 26, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Washington, D.C. (location) — Address of registrant's principal executive office
- 001-41719 (identifier) — Commission File Number
- 45-2406880 (identifier) — IRS Employer Identification Number
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond stating that this item is included in the filing.
What is the primary business of 60 Degrees Pharmaceuticals, Inc.?
60 Degrees Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, with SIC code 2834.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 26, 2024.
Where is the principal executive office of 60 Degrees Pharmaceuticals, Inc. located?
The principal executive office is located at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036.
What is the fiscal year end for 60 Degrees Pharmaceuticals, Inc.?
The fiscal year end for 60 Degrees Pharmaceuticals, Inc. is December 31st.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-28 15:59:12
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
- $1.00 — intained a minimum closing bid price of $1.00 per share required for continued listin
Filing Documents
- ea021270001-8k_60degrees.htm (8-K) — 30KB
- ea021270001ex99-1_60degrees.htm (EX-99.1) — 9KB
- image_001.gif (GRAPHIC) — 0KB
- image_002.gif (GRAPHIC) — 0KB
- image_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-073351.txt ( ) — 264KB
- sxtp-20240826.xsd (EX-101.SCH) — 4KB
- sxtp-20240826_def.xml (EX-101.DEF) — 26KB
- sxtp-20240826_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240826_pre.xml (EX-101.PRE) — 25KB
- ea021270001-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. As previously reported, on February 27, 2024, 60 Degrees Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") therein stating that for the 30 consecutive business day period between January 11, 2024 through February 27, 2024, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On August 26, 2024, the Company received a letter from the Listing Qualifications Staff of Nasdaq informing the Company that for the 10 consecutive business day period between August 12, 2024 through August 23, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is closed. On August 28, 2024, the Company issued a press release announcing its compliance with the Bid Price Rule. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release dated as of August 28, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: August 28, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President